CoChat

Dapagliflozin as add‐on therapy in Asian patients with type 2 diabetes inadequately controlled on insulin with or without oral antihyperglycemic drugs: A randomized controlled trial: 达格列净联合胰岛素治疗无论是否使用口服降糖药均血糖控制不佳的亚洲2型糖尿病患者:一项随机对照试验

Yang, Wenying, Ma, Jianhua, Li, Yiming, Li, Yanbing, Zhou, Zhiguang, Kim, Jae Hyeon, Zhao, June, Ptaszynska, Agata · 2018 · Journal of Diabetes
Cited by 58

The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.

Abstract

Background: This 24‐week Phase 3 double‐blind placebo‐controlled study assessed the safety and efficacy of dapagliflozin as add‐on to insulin, with or without oral antihyperglycemic drugs (OADs), in Asian patients with inadequately controlled type 2 diabetes mellitus. Methods: Adult patients with HbA1c between ≥7.5% and ≤10.5%, body mass index ≤45 kg/m 2, and on insulin doses ≥20 IU daily were randomized to dapagliflozin 10 mg (n = 139) or placebo (n = 133) to assess 24‐week changes in HbA1c (primary outcome), fasting plasma glucose (FPG), body weight, total daily dose of insulin (TDDI), and seated systolic blood pressure (SeSBP; exploratory outcome). Results: Baseline characteristics were similar in both groups. At Week 24, compared with placebo, dapagliflozin significantly improved HbA1c (mean [95% confidence interval] 0.03% [−0.11, 0.17] for placebo vs −0.87% [−1.00, −0.74] for dapagliflozin; between‐group difference − 0.90% [−1.09, −0.71], P < 0.0001]), FPG, body weight, TDDI, and SeSBP. The incidence of adverse events (AEs) in the dapagliflozin and placebo groups was 80.5% and 71.2%, respectively, with few patients discontinuing due to AEs (dapagliflozin, 2.2%; placebo, 4.2%). The occurrence of hypoglycemia was similar in the dapagliflozin and placebo groups (23.7% and 22.6%, respectively; no major events). The frequency of urinary tract and genital infections was low; no deaths were reported. Conclusions: Dapagliflozin as add‐on to insulin, with or without OADs, significantly improved glycemic control and reduced body weight and blood pressure in Asian patients. Dapagliflozin was well tolerated, with a similar frequency of hypoglycemia in both groups. These results support the use of dapagliflozin as add‐on to insulin, with or without OADs, in this population.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/1753-0407.12634

Cites

8 of 8 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 8 references

Cited by

See all 58

Metadata

Authors
Yang, W., Ma, J., Li, Y., Li, Y., Zhou, Z., Kim, J. H., Zhao, J., & Ptaszynska, A.
Venue
Journal of Diabetes
Publisher
Wiley
Published
2018-01-25
Volume
10
Issue
7
Pages
589-599
ISSN
  • 1753-0393 (ISSN-L)
  • 1753-0407
OpenAlex
W2772966699
Cited by
58
References
8
FWCI
3.71
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Dapagliflozin as add‐on therapy in Asian patients with type 2 diabetes inadequately controlled on insulin with or without oral antihyperglycemic drugs: A randomized controlled trial: 达格列净联合胰岛素治疗无论是否使用口服降糖药均血糖控制不佳的亚洲2型糖尿病患者:一项随机对照试验. https://app.cochat.ai/papers/10.1111/1753-0407.12634
The paper
Yang, W., Ma, J., Li, Y., Li, Y., Zhou, Z., Kim, J. H., Zhao, J., & Ptaszynska, A. (2018). Dapagliflozin as add‐on therapy in Asian patients with type 2 diabetes inadequately controlled on insulin with or without oral antihyperglycemic drugs: A randomized controlled trial: 达格列净联合胰岛素治疗无论是否使用口服降糖药均血糖控制不佳的亚洲2型糖尿病患者:一项随机对照试验. Journal of Diabetes. https://doi.org/10.1111/1753-0407.12634

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.